with their comment that we should follow the proper indications for non-invasive coronary angiography to avoid unnecessary radiation. Although it should be a small number of patients, we admit that some patients included in this study may be inappropriate indication for CCTA according to the current guideline.
2 Basically, as we retrospectively collected data from consecutive patients for a certain period of time, it was inevitable to include some patients who underwent CCTA not abided by the current guideline 2 in real clinical practice. However, we have to be careful to interpret guidelines to apply to an individual patient. Typical angina itself is not necessarily an inappropriate criterion in the current guideline. Women patients with typical angina and age ,60 years are classified as having intermediate pre-test probability which is one of appropriate criteria. In addition, patients with high-pre-test probability who are not able to exercise or whose ECG is not interpretable belong to uncertain criteria. Uncertain criteria imply both that test may be generally acceptable and may be a reasonable approach for the indication and that more research and/or patient information is needed to classify the indication definitively. Therefore, appropriateness of CCTA in this specific group of patients is still debatable or should be individualized. Otherwise, the current guideline is based on a definition that high-pre-test probability is .90% pre-test probability of coronary artery disease (CAD) which is from the invasive angiography-based guideline probabilities. However, a recent study showed that the prevalence of significant CAD on CCTA was much lower than those estimated by the invasive angiography-based guideline probabilities even in patients with typical angina (29 vs. 86%). 3 This result may suggest that many patients with high-pre-test probability estimated by current guideline are actually with intermediate pre-test probability and indicated for CCTA. In regard to diabetes, although it is not incorporated into the algorithm, it should be an important risk factor that affects pre-test likelihood of CAD. However, there is no consensus-based guideline or evidence yet about the way how to incorporate diabetes in estimating pre-test probability for CCTA indication. We have to be aware of the limitation of the current guideline for CCTA, which is mostly from
